Zedira’s general approach in medicine targets dysregulated transglutaminase activity in disease states.
In the human body, eight transglutaminases fulfill a broad variety of physiological functions. On the other hand, transglutaminases are involved in the pathophysiology of various disorders. Celiac disease, thrombosis, fibrosis or even cancer and such neurodegenerative diseases as Alzheimer’s, Huntington’s and Parkinson’s disease are just some examples.
Celiac Disease Zedira’s drug candidate ZED1227 targeting dysregulated TG2 in celiac disease is currently tested in phase I clinical trials (first-in-class).